



Published in final edited form as:

Trop Med Int Health. 2020 July ; 25(7): 886–896. doi:10.1111/tmi.13405.

Cardiovascular disease among people living with HIV in Brazil

David C. Boettiger^{1,2}, Maria Mercedes Escuder³, Matthew G. Law², Valdiléa Veloso⁴, Rosa A. Souza⁵, Maria L. R. Ikeda⁶, Paulo R. deAlencastro⁷, Unai Tupinambás⁸, Carlos Brites⁹, Beatriz Grinsztejn⁴, Jackeline O. Ggomes³, Sayonara Ribeiro⁴, Catherine C. McGowan¹⁰, Karu Jayathilake¹⁰, Jessica L. Castilho¹⁰, Alexandre Grangeiro¹¹ HIV-Brazil Cohort Study

¹Institute for Health Policy Studies, University of California, San Francisco, CA, USA

²Kirby Institute, University of New South Wales, Sydney, Australia

³São Paulo State Department of Health, Institute of Health, São Paulo, Brazil

⁴National Institute of Infectology – Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil

⁵São Paulo State Department of Health, AIDS Reference and Training Center, São Paulo, Brazil

⁶School of Health, University do Vale do Rio dos Sinos, Porto Alegre, Brazil

⁷Care and Treatment Clinic of the Hospital Sanatório Partenon, Rio Grande do Sul State Department of Health, Porto Alegre, Brazil

⁸Medical School, Federal University of Minas Gerais, Belo Horizonte, Brazil

⁹Edgar Santos University Hospital Complex, Federal University of Bahia, Salvador, Brazil

¹⁰Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN, USA

¹¹Department of Preventive Medicine, University of São Paulo School of Medicine, São Paulo, Brazil

Abstract

OBJECTIVES—There is a paucity of data on cardiovascular disease (CVD) among people living with HIV (PLHIV) in resource-limited countries. We assessed factors associated with CVD and the impact of prevalent CVD on all-cause mortality in PLHIV on antiretroviral therapy in Brazil.

METHODS—Competing risk regression to assess factors associated with CVD and all-cause mortality in the HIV-Brazil Cohort Study between 2003 and 2014.

RESULTS—Among 5614 patients, the rate of CVD was 3.5 (95% confidence interval [95% CI] 2.9–4.3) per 1000 person-years. CVD was associated with older age (adjusted hazard ratio [aHR]

Corresponding Author David C. Boettiger, Institute for Health Policy Studies, 3333 California St, University of California, San Francisco, CA, USA. Tel: +1 415 502 4544; dboettiger@kirby.unsw.edu.au.

Sustainable Development Goals (SDGs): SDG 3 (good health and well-being), SDG 10 (reduced inequalities), SDG 17 (partnerships for the goals)

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Figure S1. Probability of cardiovascular disease by sex and age (excluding patients with a history of CVD at baseline).

Table S1. Factors associated with cardiovascular disease (excluding patients with a history of CVD at baseline).

6.4 for ≥55 years vs. <35 years, 95% CI: 2.5–16.3, $P < 0.01$), black race (aHR 1.8 vs. white race, 95% CI: 1.0–3.1, $P = 0.04$), past CVD (aHR 3.0 vs. no past CVD, 95% CI: 1.4–6.2, $P < 0.01$), hypertension (aHR 1.8 vs. no hypertension, 95% CI: 1.0–3.1, $P = 0.04$), high-grade dyslipidemia (aHR 9.3 vs. no high-grade dyslipidemia, 95% CI: 6.0–14.6, $P < 0.01$), ever smoking (aHR 2.4 vs. never, 95% CI: 1.2–5.0, $P = 0.02$) and low nadir CD4 cell count (aHR 1.8 for 100–250 cells/mm³ vs. >250 cells/mm³, 95% CI: 1.0–3.2, $P = 0.05$). The rate of death was 16.6 (95% CI: 15.1–18.3) per 1000 person-years. Death was strongly associated with having had a past CVD event (aHR 1.7 vs. no past CVD event, 95% CI: 1.1–2.7, $P = 0.01$).

CONCLUSIONS—Traditional and HIV-specific factors associated with CVD among PLHIV in Brazil are similar to those identified among PLHIV in high-income countries. PLHIV in Brazil with a history of CVD have a high risk of death. CVD care and treatment remain priorities for PLHIV in Brazil as this population ages and antiretroviral therapy use expands.

Keywords

HIV; cardiovascular disease; mortality; Brazil; antiretroviral therapy

Introduction

Studies from high-income countries have shown that people living with HIV (PLHIV) have about a twofold increased risk of cardiovascular disease (CVD) compared to their HIV-uninfected peers.[1] However, there is a paucity of data on CVD among PLHIV in resource-limited countries.[2–4]

Brazil is an important country to study long-term health outcomes among PLHIV, given its early availability of antiretroviral therapy (ART). Like many other middle-income countries, the prevalence of CVD and other non-communicable diseases in Brazil is increasing in the general population.[5–8] Despite this, recent evidence from the HIV-Brazil Cohort Study suggests CVD incidence has plateaued among PLHIV.[9] Clinical factors that may be influencing this trend have not been described. Further, it is uncertain to what extent past CVD is a risk factor for mortality among PLHIV in Brazil. In the general population [10–12] and among PLHIV [13] in high-income settings, past CVD has been shown to approximately double the risk of all-cause mortality.

We sought to address these knowledge gaps. Determining key factors associated with CVD and the influence of past CVD on all-cause mortality among PLHIV in Brazil will aid the allocation of healthcare resources and allow policymakers and researchers to estimate the effectiveness of potential CVD prevention methods in this population.

Methods

Study population

We used data collected between January 2003 and December 2014 from seven HIV clinics with validated CVD outcomes in the HIV-Brazil Cohort Study, a longitudinal cohort study of adults initiating ART.[14] The sites involved were São Paulo State Department of Health STD/AIDS Referral and Training Center, São Paulo; Professor Edgard Santos University

Hospital, Salvador; National Institute on Infectology Evandro Chagas – Fiocruz, Rio De Janeiro; Hospital Sanatório Partenon, Porto Alegre; Municipal Specialized Treatment Facility, San Jose Rio Preto; Santana Municipal Network, São Paulo; and Federal University of Minas Gerais, Belo Horizonte.

Ethics

The HIV-Brazil Cohort Study protocol was approved by the Institutional Review Boards of participating sites according to the Brazilian regulation for research with human subjects. Written informed consent was waived for retrospectively collected data; however, all enrolled patients provided written informed consent to contribute prospectively collected data.

Inclusion criteria

Patients were included in our CVD analysis if they had documentation of at least one day of follow-up on ART. Our mortality analysis focused on characterising the impact of prior CVD in patients' stable on ART (defined as having been on ART for at least six months) so that our results would not be dominated by the high rate of AIDS-associated mortality early after ART initiation.[15] Patients included in the CVD analysis who had, or developed, a history of CVD were included in the mortality analysis from the date of their first CVD event or 6 months after ART initiation, whichever came last, alongside those in the CVD analysis who did not experience a CVD event who were included from six months after ART initiation.

Definitions

Baseline for our CVD analysis was defined as the date of ART initiation, and baseline for our mortality analysis was defined as six months after ART initiation or the date of first CVD event, whichever came last (6 months after ART initiation was defined as baseline for those without documentation of a CVD event). ART was defined as three or more antiretroviral drugs in a single regimen. The window period for baseline CD4 cell count, CD4/CD8 ratio and HIV viral load was between baseline and six months before baseline. When more than one measurement was available in the window period, the measurement taken closest to baseline was used. Nadir CD4 cell count was defined as the lowest CD4 cell count documented prior to ART initiation. Time-updated data were not available on smoking status, but we were able to define patients as ever or never having smoked based on information documented at ART initiation.

CVD was defined as non-fatal myocardial infarction, cardiac ischaemia, angina, coronary artery disease, angioplasty, non-fatal stroke or transient ischaemic attack. Cause of death information was not available, and therefore, we were unable to include fatal myocardial infarction or fatal stroke in our CVD definition. CVD, diabetes (fasting blood glucose ≥ 126 mg/dL, random blood glucose ≥ 200 mg/dL, or haemoglobin A1c $> 6.5\%$) and high-grade dyslipidemia (total cholesterol ≥ 300 mg/dL, low-density lipoprotein ≥ 190 mg/dL, or triglyceride > 500 mg/dL) diagnoses were validated by chart review performed by clinicians at contributing sites. Events were 'confirmed' where a definitive medical report, such as a laboratory report or radiographic report, was present along with documentation of the

diagnosis in the medical record. Events were defined as ‘probable’ when there was a documented diagnosis in the medical record supported by the initiation of treatment for that diagnosis or medical test data, or the diagnosis being cited as probable in a consultation note, hospital discharge summary or autopsy report. Events were ‘possible’ when a diagnosis was based on clinical examination without further investigation, or the patient self-reported a diagnosis with evidence of receiving appropriate treatment. We included all levels of certainty as a positive diagnosis. Hypertension diagnoses were not validated; however, positive diagnoses were defined as confirmed systolic blood pressure >140 mmHg, confirmed diastolic blood pressure >90 mmHg, treatment with an antihypertensive drug or documentation of a positive diagnosis in the medical record.

Loss to follow-up was defined as the absence of patient contact for more than 12 months and failure to identify the patient in the national death registry, as described in.[14]

Statistical analysis

Cumulative incidence plots and competing risk regression were used to assess factors associated with CVD and all-cause mortality. In the CVD analysis, follow-up was censored at the last recorded clinic visit, and loss to follow-up and death were considered competing events. In the mortality analysis, follow-up was censored at the last recorded clinic visit, and loss to follow-up was considered a competing event. Follow-up time was left truncated in the mortality analysis so that patients who developed CVD after 6 months of ART would begin contributing time on ART from a point consistent with their total duration of ART use at that time rather than from the origin.

Sex, race, mode of HIV exposure, past CVD, smoking status at ART initiation, nadir CD4 cell count at ART initiation, AIDS diagnosis prior to ART initiation, year of ART initiation and HIV clinic were analyzed as fixed covariates. Age, hypertension, dyslipidemia, diabetes, CD4 cell count, CD4/CD8 ratio, HIV viral load, abacavir use and protease inhibitor use were evaluated as time-updated covariates. We focused our evaluation of ART in the CVD analysis on abacavir and protease inhibitors as both have previously been found to be associated with CVD.[16–18]

All evaluated covariates were included in our multivariate models unless there was substantial correlation detected between covariates, in which case only the most statistically significant covariate was retained. We did not include nadir CD4 cell count, CD4 cell count or CD4/CD8 ratio together in our multivariate analyses given the clinical similarity of these measures. For simplicity, we have labelled sub-distribution hazard ratios generated from our competing risk regression models as hazard ratios (HRs). Patients with missing data were included in all analyses, but we do not report HRs for missing categories.

Many studies of CVD in PLHIV have excluded patients with a history of CVD at ART initiation.[2,16,18–20] We did not make this exclusion to make our results as relevant as possible to physicians managing the CVD risk of all presenting PLHIV. Nevertheless, in the interest of making our results more directly comparable with those of others, we conducted an alternate CVD analysis whereby PLHIV with existing CVD at ART initiation were excluded.

All data management was conducted with SAS 9.4 (SAS Institute, Inc, Cary, North Carolina) and all statistical analyses with Stata 14 (Stata Corp., College Station, Texas).

Results

Of 6204 patients included in the HIV-Brazil Cohort Study, 5614 (90.5%) had at least one day of follow-up on ART. Of these, 96 (1.7%) experienced a CVD event after ART initiation; 58 events were due to coronary artery dysfunction and 38 events were due to cerebrovascular dysfunction. The overall rate of CVD was 3.5 (95% confidence interval [95% CI] 2.9–4.3) per 1000 person-years. Rates of coronary artery dysfunction and cerebrovascular dysfunction were 2.1 (95% CI: 1.6–2.7) and 1.4 (95% CI: 1.0–1.9) per 1000 person-years, respectively. There were 5381 patients with more than six months of follow-up on ART who were included in our mortality analysis, among whom 418 (7.8%) died during follow-up. The overall rate of death was 16.6 (95% CI: 15.1–18.3) per 1000 person-years. Table 1 displays the baseline characteristics of both our CVD analysis population and our mortality analysis population. The rate of loss to follow-up in our CVD analysis was 4.4 (95% CI: 3.6–5.2) per 1000 person-years, and in our mortality analysis, it was 4.5 (95% CI: 3.7–5.4) per 1000 person-years.

CVD was associated with both traditional and HIV-specific risk factors (Figure 1 and Table 2). Traditional risk factors included older age (adjusted HR [aHR] 6.4 for ≥55 years vs. <35 years, 95% CI: 2.5–16.3, $P < 0.01$), black race (aHR 1.8 vs. white race, 95% CI: 1.0–3.1, $P = 0.04$), past CVD (aHR 3.0 vs. no past CVD, 95% CI: 1.4–6.2, $P < 0.01$), hypertension (aHR 1.8 vs. no hypertension, 95% CI: 1.0–3.1, $P = 0.04$), high-grade dyslipidemia (aHR 9.3 vs. no high-grade dyslipidemia, 95% CI: 6.0–14.6, $P < 0.01$) and ever smoking (aHR 2.4 vs. never, 95% CI: 1.2–5.0, $P = 0.02$). The main HIV-specific risk factor was lower nadir CD4 cell count (aHR 1.8 for 100–250 cells/mm³ vs. >250 cells/mm³, 95% CI: 1.0–3.2, $P = 0.05$). Other immune markers, HIV viral load, abacavir use and protease inhibitor use were not significantly associated with CVD. Similar results were seen in our alternate model excluding PLHIV with existing CVD at ART initiation, although CVD rates were generally lower (Figure S1 and Table S1).

Figure 2 and Table 3 show that death on ART was strongly associated with having had a past CVD event (aHR 1.7 vs. no past CVD event, 95% CI: 1.1–2.7, $P = 0.01$). Other predictive factors included older age (aHR 2.0 for ≥55 years vs. <35 years, 95% CI: 1.4–3.0, $P < 0.01$), male sex (aHR 1.3 vs. female, 95% CI: 1.0–1.6, $P = 0.05$), mixed black race (aHR 1.3 vs. white race, 95% CI: 1.0–1.7, $P = 0.02$), exposure to HIV via intravenous drug use (aHR 1.7 vs. heterosexual exposure, 95% CI: 1.2–2.5, $P < 0.01$), diabetes (aHR 1.6 vs. no diabetes, 95% CI: 1.1–2.2, $P = 0.02$), low CD4 cell count (aHR 7.7 for <200 cells/mm³ vs. >500 cells/mm³, 95% CI: 5.6–10.6, $P < 0.01$), low CD4/CD8 ratio (aHR 2.5 for <0.4 vs. >0.7, 95% CI: 1.8–3.4, $P < 0.01$), detectable HIV viral load (aHR 2.1 vs. undetectable, 95% CI: 1.7–2.7, $P < 0.01$) and earlier year of ART initiation (aHR 1.5 for 2000–2004 vs. 2010–2014, 95% CI: 1.0–2.1, $P = 0.04$). There were also significant differences in mortality rate among HIV clinics (see Table 3).

Discussion

CVD events occur in approximately 0.35% of PLHIV per year in Brazil. We found events were associated with both traditional and HIV-specific risk factors. Further, we have shown that a history of CVD increases the hazard of all-cause mortality by approximately 70% among PLHIV in Brazil.

Earlier work from the Data collection on Adverse events of Anti-HIV Drugs (D:A:D) cohort, which follows PLHIV in Europe, the US, Australia and Argentina, found CVD occurred at a rate of 5.4 per 1000 person-years.[16] This cohort was of a similar age to ours but the analysis included fatal CVD events and coronary artery bypass graft in the definition of CVD, neither of which were in our definition. This may explain why we found a lower rate of CVD. Globally, estimated crude rates of myocardial infarction and stroke among PLHIV are consistent with our findings for Brazil.[1] Unfortunately however, data from resource-limited countries are scarce. In a single-centre study conducted in Rio de Janeiro, in which a broad definition of CVD was employed (any death or hospitalisation associated with heart or vascular disease, ischaemic heart disease, stroke, venous thromboembolism or pulmonary embolism), the incidence of CVD among 2960 PLHIV was 6.8 per 1000 person-years.[2] Among a cohort involving HIV clinics in high- and middle-income Asian countries, Bijker et al found a CVD event rate of 2.2 per 1000 person-years.[3] The authors of the Asian study suggest their low CVD rate may be explained by underdiagnosis of CVD. In lower resource settings, limited accessibility of screening and diagnostic tools may result in high rates of missed CVD diagnosis. Moreover, HIV-associated stigma has been described as a major barrier to healthcare utilisation among PLHIV in resource-limited settings.[21] Given our CVD event rate for Brazil was comparable to rates reported from high-income areas, it may be that true rates of CVD and rates of missed diagnosis are similar for PLHIV in these settings. Alternatively, this finding could also be explained by a high true rate of CVD in Brazil being met by high rates of missed diagnosis.

The traditional risk factors we found associated with CVD in PLHIV were similar to those reported in earlier studies from high-income and resource-limited settings.[2,3,16,19] Consistent with our findings, Diaz et al also found that low nadir CD4 cell count was associated with CVD among PLHIV in Rio de Janeiro.[2] Low CD4 levels and detectable viral load are linked to chronic immune activation and inflammation in HIV-infected persons, contributing to atherosclerosis development via HIV-mediated endothelial injury and the promotion of a pro-thrombotic state.[22] Larger studies from high-income settings have also found that CVD in PLHIV is associated with abacavir and protease inhibitor use. [16,17,19] Results regarding the CVD risk of abacavir have been particularly controversial. [20,23–29] However, given the very low rate of abacavir use in Brazil, our results do not substantially influence this debate. Protease inhibitor use, although not significant in our multivariate model, was associated with a small increase in the risk of CVD which is consistent with earlier work.[16]

Short-term and long-term survival after myocardial infarction or stroke has improved substantially over the past 20 years in high-income countries, most likely due to improvements in revascularisation, effective acute treatment and long-term secondary

prevention.[30,31] Nevertheless, current evidence indicates that CVD survivors remain at a twofold higher risk of all-cause mortality for up to ten years after their event when compared with age-matched members of the general population.[10–12] Our findings for PLHIV in Brazil are consistent with this data, suggesting the added risk of mortality after a CVD event is not influenced by HIV. Supporting this notion, a French study evaluating one-year mortality rates in myocardial infarction survivors found no difference between patients with and without HIV.[13] Although there is evidence among the English general population that increased mortality associated with past CVD is strongly influenced by age and gender,[11] the low number of patients with a history of CVD in our analysis precluded us from investigating such differences.

This multisite study draws from a diverse clinical population in Brazil. The comprehensive data collected were strengthened by standardised validation of CVD. Our study also leveraged the Brazilian national systems of HIV laboratory data and death registry. Nevertheless, there were some important limitations. Firstly, the low number of CVD events meant our analysis was underpowered to detect a significant effect of some well-known CVD risk factors, for example sex and CD4 cell count. We also had limited data on some important variables including fatal myocardial infarction and fatal stroke, time-updated smoking status and validated low-grade dyslipidemia.

This study emphasises the importance of managing both traditional and HIV-specific factors to reduce CVD risk among ART users in Brazil. We have also demonstrated that PLHIV with a history of CVD have a high risk of death on ART. CVD care and treatment remain priorities for PLHIV in Brazil as this population ages and ART use expands.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We acknowledge all individuals who assisted with this study. Health Institute, São Paulo State Department of Health: Guilherme Berto Calvino, Angelica Marta Lopes, Claudia di Maria Medori Mafredo. Care and Treatment Clinic of the Partenon Sanatorium: Sonia Maria de Alencastro Coracini, Claudia Penalvo, Gabriela Almeida. Edgar Santos University Hospital Complex: Estela Luz. AIDS Reference and Training Center: Anita Sevzatian Terzian, Gabriela R. Waghbi, Rejane Alves Fraissat, and Simone Queiróz Rocha. Vanderbilt University Medical Center: Stephany Duda and the members of the CCASAnet Data Coordinating Center.

The HIV-Brazil Cohort Study was supported by the Brazilian National Council for Scientific & Technological Development, Brazilian National Ministry of Health, and Pan American Health Organization. The study was supported in part by the U.S. National Institutes of Health (NIH) (K23AI1120875 and P30AI110527) and the NIHfunded Caribbean, Central and South America network for HIV epidemiology (CCASAnet), a member cohort of the International epidemiology Databases to Evaluate AIDS (IeDEA) (U01AI069923). This award is funded by the following institutes: Eunice Kennedy Shriver National Institute Of Child Health & Human Development (NICHD), National Cancer Institute (NCI), National Institute Of Allergy And Infectious Diseases (NIAID), National Institute Of Mental Health (NIMH), and the Office Of The Director, National Institutes Of Health (OD).

References

1. Shah ASV, Stelzle D, Lee KK et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV. *Circulation* 2018; 138: 1100–1112. [PubMed: 29967196]

2. Diaz CM, Segura ER, Luz PM et al. Traditional and HIV-specific risk factors for cardiovascular morbidity and mortality among HIV-infected adults in Brazil: a retrospective cohort study. *BMC Infect Dis* 2016; 16: 376. [PubMed: 27503230]
3. Bijker R, Jiamsakul A, Uy E et al. Cardiovascular disease-related mortality and factors associated with cardiovascular events in the TREAT Asia HIV Observational Database (TAHOD). *HIV Med* 2019; 20: 183–191. [PubMed: 30620108]
4. Walker RW, Jusabani A, Aris E et al. Stroke risk factors in an incident population in urban and rural Tanzania: a prospective, community-based, case-control study. *Lancet Global Health* 2013; 1: e282–288. [PubMed: 24748275]
5. Duncan BB, Franca EB, Passos VMA et al. The burden of diabetes and hyperglycemia in Brazil and its states: findings from the Global Burden of Disease Study 2015. *Rev Bras Epidemiol* 2017; 20(suppl 1): 90–101.
6. Malta DC, Santos NB, Perillo RD, Szwarcwald CL. Prevalence of high blood pressure measured in the Brazilian population, National Health Survey, 2013. *Sao Paulo Med J* 2016; 134: 163–170. [PubMed: 27224281]
7. Malta DC, Szwarcwald CL. Lifestyles and chronic non-transmissible diseases of the Brazilian population according to the National Health Survey: balance of the main results. *Sao Paulo Med J* 2015; 133: 286–289. [PubMed: 26517145]
8. Schmidt MI, Duncan BB, Azevedo e Silva G et al. Chronic non-communicable diseases in Brazil: burden and current challenges. *Lancet* 2011; 377: 1949–1961. [PubMed: 21561658]
9. Castilho JL, Escuder MM, Veloso V et al. Trends and predictors of non-communicable disease multimorbidity among adults living with HIV and receiving antiretroviral therapy in Brazil. *J Int AIDS Soc* 2019; 22: e25233. [PubMed: 30697950]
10. Schmidt M, Szepligeti S, Horvath-Puho E, Pedersen L, Botker HE, Sorensen HT. Long-term survival among patients with myocardial infarction before age 50 compared with the general population: a Danish Nationwide Cohort Study. *Circ Cardiovasc Qual Outcomes* 2016; 9: 523–531. [PubMed: 27576336]
11. Smolina K, Wright FL, Rayner M, Goldacre MJ. Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010. *Circ Cardiovasc Qual Outcomes* 2012; 5: 532–540. [PubMed: 22740013]
12. Bronnum-Hansen H, Davidsen M, Thorvaldsen P, Danish MSG. Long-term survival and causes of death after stroke. *Stroke* 2001; 32: 2131–2136. [PubMed: 11546907]
13. Lorgis L, Cottenet J, Molins G et al. Outcomes after acute myocardial infarction in HIV-infected patients: analysis of data from a French nationwide hospital medical information database. *Circulation* 2013; 127: 1767–1774. [PubMed: 23543004]
14. Grangeiro A, Escuder MM, Cassenote AJ et al. The HIV-Brazil cohort study: design, methods and participant characteristics. *PLoS ONE* 2014; 9: e95673. [PubMed: 24789106]
15. Gupta A, Nadkarni G, Yang WT et al. Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. *PLoS ONE* 2011; 6: e28691. [PubMed: 22220193]
16. Friis-Moller N, Ryom L, Smith C et al. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. *Eur J Prev Cardiol* 2016; 23: 214–223. [PubMed: 25882821]
17. Sabin CA, Reiss P, Ryom L et al. Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. *BMC Med* 2016; 14: 61. [PubMed: 27036962]
18. Elion RA, Althoff KN, Zhang J et al. Recent Abacavir use increases risk of type 1 and type 2 myocardial infarctions among adults with HIV. *J Acquir Immune Defic Syndr* 2018; 78: 62–72. [PubMed: 29419568]
19. Drozd DR, Kitahata MM, Althoff KN et al. Increased risk of myocardial infarction in HIV-infected individuals in North America compared with the general population. *J Acquir Immune Defic Syndr* 2017; 75: 568–576. [PubMed: 28520615]

20. Obel N, Farkas DK, Kronborg G et al. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. *HIV Med* 2010; 11: 130–136. [PubMed: 19682101]
21. Mahajan AP, Sayles JN, Patel VA et al. Stigma in the HIV/AIDS epidemic: a review of the literature and recommendations for the way forward. *AIDS* 2008; 22(Suppl 2): S67–S79.
22. Zanni MV, Grinspoon SK. HIV-specific immune dysregulation and atherosclerosis. *Curr HIV/AIDS Rep* 2012; 9: 200–205. [PubMed: 22638983]
23. Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. *Clin Infect Dis* 2011; 53: 84–91. [PubMed: 21653308]
24. Brothers CH, Hernandez JE, Cutrell AG et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. *J Acquir Immune Defic Syndr* 2009; 51: 20–28. [PubMed: 19282778]
25. Brouwer ES, Napravnik S, Eron JJ Jr et al. Effects of combination antiretroviral therapies on the risk of myocardial infarction among HIV patients. *Epidemiology* 2014; 25: 406–417 [PubMed: 24713880]
26. Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, Shlipak MG. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. *AIDS* 2011; 25: 1289–1298. [PubMed: 21516027]
27. Cruciani M, Zanichelli V, Serpelloni G et al. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. *AIDS* 2011; 25: 1993–2004. [PubMed: 21716077]
28. Desai M, Joyce V, Bendavid E et al. Risk of cardiovascular events associated with current exposure to HIV antiretroviral therapies in a US veteran population. *Clin Infect Dis* 2015; 61: 445–452. [PubMed: 25908684]
29. Ding X, Andraca-Carrera E, Cooper C et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. *J Acquir Immune Defic Syndr* 2012; 61: 441–447. [PubMed: 22932321]
30. Nauta ST, Deckers JW, Akkerhuis KM, van Domburg RT. Short- and long-term mortality after myocardial infarction in patients with and without diabetes: changes from 1985 to 2008. *Diabetes Care* 2012; 35: 2043–2047. [PubMed: 22815296]
31. Schmidt M, Jacobsen JB, Johnsen SP, Botker HE, Sorensen HT. Eighteen-year trends in stroke mortality and the prognostic influence of comorbidity. *Neurology* 2014; 82: 340–350. [PubMed: 24363134]




Figure 1. Probability of cardiovascular disease by sex and age. CVD, cardiovascular disease; yo, years old.




Figure 2. Probability of death on antiretroviral therapy with and without prior cardiovascular disease. CVD, cardiovascular disease.

Table 1

Baseline characteristics*

Characteristic		CVD analysis (n = 5614)	Mortality analysis (n = 5381)
Age, years	Median (IQR)	36.8 (30.4–44.3)	36.8 (30.3–44.3)
Sex	Male	3750 (66.8)	3586 (66.6)
	Female	1864 (33.2)	1795 (33.4)
Race	White	3032 (54.0)	2916 (54.2)
	Black	972 (17.3)	927 (17.2)
	Mixed black	1332 (23.7)	1277 (23.7)
	Other	278 (5.0)	261 (4.9)
HIV exposure	Heterosexual	2956 (52.7)	2845 (52.9)
	Men who have sex with men	1685 (30.0)	1628 (30.3)
	Intravenous drug use	177 (3.2)	170 (3.2)
	Other	796 (14.2)	738 (13.7)
Past cardiovascular disease	No	5541 (98.7)	5232 (97.2)
	Yes	73 (1.3)	149 (2.8)
Hypertension	No	5130 (91.4)	4867 (90.5)
	Yes	484 (8.6)	514 (9.6)
High-grade dyslipidemia	No	5441 (96.9)	5110 (95.0)
	Yes	173 (3.1)	271 (5.0)
Diabetes	No	5448 (97.0)	5192 (96.5)
	Yes	166 (3.0)	189 (3.5)
Smoking status at ART initiation	Never	1399 (24.9)	1324 (24.6)
	Ever	2897 (51.6)	2803 (52.1)
	Unknown	1318 (23.5)	1254 (23.3)
Nadir CD4 at ART initiation, cells/mm ³	Median (IQR)	208 (93–292)	208 (95–292)
	Unknown	207 (3.7)	202 (3.8)
CD4, cells/mm ³	Median (IQR)	234 (116–327)	351 (223–484)
	Unknown	562 (10.0)	707 (13.1)
CD4/CD8 ratio	Median (IQR)	0.24 (0.13–0.39)	0.36 (0.22–0.56)
	Unknown	1872 (33.4)	1659 (30.8)

Characteristic	CVD analysis (n = 5614)	Mortality analysis (n = 5381)
HIV viral load, copies/ml	42 590 (7433–142 968)	0 (0–65)
Median (IQR)	971 (17.3)	768 (14.3)
AIDS diagnosis prior to ART initiation	3550 (63.2)	3406 (63.3)
	2064 (36.8)	1975 (36.7)
Abacavir use	5567 (99.2)	5320 (98.9)
	47 (0.8)	61 (1.1)
Protease inhibitor use	3974 (70.8)	3590 (66.7)
	1640 (29.2)	1791 (33.3)
Year of ART initiation	800 (14.3)	783 (14.6)
	2264 (40.3)	2191 (40.7)
	2550 (45.4)	2407 (44.7)
HIV clinic	907 (16.2)	867 (16.1)
	356 (6.3)	317 (5.9)
	1939 (34.5)	1892 (35.2)
	1268 (22.6)	1200 (22.3)
	384 (6.8)	376 (7.0)
	247 (4.4)	236 (4.4)
	513 (9.1)	493 (9.2)

CVD, cardiovascular disease; IQR, interquartile range; ART, antiretroviral therapy; CRT, São Paulo State Department of Health STD/AIDS Referral and Training Center; HUPES, Professor Edgard Santos University Hospital; INI, National Institute of Infectology Evandro Chagas – Fiocruz; UFMG, Federal University of Minas Gerais.

* Baseline for CVD analysis was the date of ART initiation while baseline for the mortality analysis was six months after ART initiation or the date of first CVD event, whichever came last (six months after ART initiation was defined as baseline for those without documentation of a CVD event). All values are *n* (% total) unless otherwise indicated.

Table 2

Factors associated with cardiovascular disease

Characteristic	CVD events	Person-years	Rate per 1000 person-years (95% CI)	Univariate		Multivariate	
				HR (95% CI)	P	HR (95% CI)	P
Overall	96	27 328.7	3.5 (2.9-4.3)	1.0		1.0	
Age, years							
<35	7	8408.6	0.8 (0.4-1.7)	1.0		1.0	
35-44	24	10 139.1	2.4 (1.6-3.5)	3.2 (1.4-7.3)	0.01	2.4 (1.0-5.5)	0.05
45-54	35	6419.0	5.5 (3.9-7.6)	7.8 (3.5-17.4)	<0.01	3.9 (1.6-9.4)	<0.01
55+	30	2362.0	12.7 (8.9-18.2)	18.1 (8.0-41.1)	<0.01	6.4 (2.5-16.3)	<0.01
Sex							
Female	31	9570.7	3.2 (2.3-4.6)	1.0		1.0	
Male	65	17 758.0	3.7 (2.9-4.7)	1.1 (0.7-1.7)	0.67	1.4 (0.8-2.3)	0.20
Race							
White	48	15 520.4	3.1 (2.3-4.1)	1.0		1.0	
Black	20	4511.0	4.4 (2.9-6.9)	1.4 (0.8-2.3)	0.23	1.8 (1.0-3.1)	0.04
Mixed black	26	6080.4	4.3 (2.9-6.3)	1.3 (0.8-2.1)	0.24	1.5 (0.9-2.6)	0.12
Other	2	1217.0	1.6 (0.4-6.6)	0.5 (0.1-2.1)	0.37	0.5 (0.1-2.1)	0.34
HIV exposure							
Heterosexual	60	15 253.9	3.9 (3.1-5.1)	1.0		1.0	
Men who have sex with men	23	8117.7	2.8 (1.9-4.3)	0.7 (0.4-1.2)	0.18	1.0 (0.6-1.9)	0.89
Intravenous drug use							
Yes	2	974.3	2.1 (0.5-8.2)	0.5 (0.1-2.0)	0.33	0.8 (0.2-3.6)	0.82
Other	11	2982.9	3.7 (2.0-6.7)	0.8 (0.4-1.5)	0.50	1.0 (0.5-2.0)	0.92
Past CVD event							
No	82	27 019.6	3.0 (2.4-3.8)	1.0		1.0	
Yes	14	309.2	45.3 (26.8-76.5)	14.3 (8.0-25.8)	<0.01	3.0 (1.4-6.2)	<0.01
Current hypertension							
No	56	24 084.1	2.3 (1.8-3.0)	1.0		1.0	
Yes	40	3244.6	12.3 (9.0-16.8)	5.6 (3.7-8.5)	<0.01	1.8 (1.0-3.1)	0.04
Current high-grade dyslipidemia							
No	42	24 898.9	1.7 (1.2-2.3)	1.0		1.0	
Yes	54	2429.8	22.2 (17.0-29.0)	15.6 (10.2-23.9)	<0.01	9.3 (6.0-14.6)	<0.01
Current diabetes*							
No	84	25 880.1	3.2 (2.6-4.0)	1.0		1.0	
Yes	12	1448.6	8.3 (4.7-14.6)	2.6 (1.4-4.9)	<0.01	-	
Smoking status at ART initiation							
Never	10	6390.2	1.6 (0.8-2.9)	1.0		1.0	
Ever	75	14 439.7	5.2 (4.1-6.5)	3.3 (1.7-6.4)	<0.01	2.4 (1.2-5.0)	0.02
Unknown	11	6498.9	1.7 (0.9-3.1)	-		-	
Nadir CD4 at ART initiation, cells/mm ³							
>250	20	8375.8	2.4 (1.5-3.7)	1.0		1.0	

Characteristic	CVD events	Person-years	Rate per 1000 person-years (95% CI)	Univariate		Multivariate	
				HR (95% CI)	P	HR (95% CI)	P
	100–250	10 319.0	3.7 (2.7–5.1)	1.6 (0.9–2.8)	0.08	1.8 (1.0–3.2)	0.05
	<100	7369.9	3.7 (2.5–5.3)	1.6 (0.9–2.8)	0.12	1.5 (0.8–2.9)	0.21
	Unknown	1264.1	8.7 (4.8–15.7)	–	–	–	–
	>500	12 287.0	3.3 (2.4–4.4)	1.0	1.0	1.0	1.0
Current CD4 ⁺ cells/mm ³	350–500	6056.0	2.3 (1.4–3.9)	0.7 (0.4–1.2)	0.17	0.7 (0.3–1.2)	0.20
	200–349	5299.3	6.0 (4.3–8.5)	1.6 (1.0–2.6)	0.08	1.6 (0.9–2.8)	0.11
	<200	3390.4	2.4 (1.2–4.7)	0.5 (0.3–1.1)	0.10	0.6 (0.3–1.3)	0.23
	Unknown	296.0	6.8 (1.7–27.0)	–	–	–	–
Current CD4/CD8 ratio [†]	>0.7	7262.9	3.2 (2.1–4.8)	1.0	1.0	1.0	1.0
	0.4–0.7	8138.3	2.5 (1.6–3.8)	0.7 (0.4–1.4)	0.33	0.8 (0.4–1.4)	0.38
	<0.4	9260.5	4.3 (3.2–5.9)	1.2 (0.7–2.0)	0.56	1.3 (0.8–2.4)	0.32
	Unknown	2667.1	4.9 (2.8–8.4)	–	–	–	–
Current HIV viral load	Undetectable	22 003.2	3.7 (3.0–4.6)	1.0	1.0	1.0	1.0
	Detectable	4893.2	2.5 (1.4–4.3)	0.5 (0.3–1.0)	0.04	0.7 (0.4–1.4)	0.29
	Unknown	432.3	4.6 (1.2–18.5)	–	–	–	–
AIDS diagnosis prior to ART initiation	No	16 964.1	3.4 (2.6–4.4)	1.0	1.0	1.0	1.0
	Yes	10 364.6	3.7 (2.7–5.0)	1.1 (0.7–1.6)	0.73	0.8 (0.5–1.2)	0.22
Current abacavir use	No	26 891.1	3.5 (2.9–4.3)	1.0	1.0	1.0	1.0
	Yes	437.6	4.6 (1.1–18.3)	1.2 (0.3–4.9)	0.79	0.8 (0.2–3.3)	0.78
Current protease inhibitor use	No	16 067.0	3.4 (2.6–4.4)	1.0	1.0	1.0	1.0
	Yes	11 261.7	3.7 (2.8–5.0)	1.2 (0.8–1.7)	0.49	1.1 (0.7–1.8)	0.53
Year of ART initiation	2000–2004	6696.9	3.1 (2.0–4.8)	1.0	1.0	1.0	1.0
	2005–2009	13 609.5	4.3 (3.3–5.5)	1.2 (0.7–1.9)	0.50	1.1 (0.6–2.1)	0.85
	2010–2014	7022.3	2.4 (1.5–3.9)	0.6 (0.3–1.1)	0.07	0.5 (0.2–1.0)	0.06
HIV clinic	CRT	4579.0	2.4 (1.3–4.3)	1.0	1.0	1.0	1.0
	HUPES	1012.8	3.0 (1.0–9.2)	1.2 (0.3–4.1)	0.82	0.8 (0.2–3.3)	0.72
	INI	10 235.3	4.7 (3.5–6.2)	2.0 (1.1–3.8)	0.04	0.8 (0.4–1.8)	0.66
	Parrenon	5693.0	3.0 (1.9–4.8)	1.3 (0.6–2.7)	0.55	1.2 (0.5–2.8)	0.62
	Rio Preto	2203.4	2.7 (1.2–6.1)	1.2 (0.4–3.2)	0.73	1.2 (0.4–3.3)	0.74
	Santana	1098.9	2.7 (0.9–8.5)	1.2 (0.3–4.4)	0.75	1.0 (0.3–3.8)	0.99

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Characteristic	CVD events	Person-years	Rate per 1000 person-years (95% CI)	Univariate		Multivariate	
				HR (95% CI)	P	HR (95% CI)	P
UFMG	8	2506.3	3.2 (1.6–6.4)	1.4 (0.6–3.5)	0.48	1.7 (0.6–4.7)	0.30

CI, confidence interval; HR, sub-distribution hazard ratio; CVD, cardiovascular disease; ART, antiretroviral therapy; CRT, São Paulo State Department of Health STD/AIDS Referral and Training Center; HUPES, Professor Edgard Santos University Hospital; INI, National Institute of Infectology Evandro Chagas – Fiocruz; UFMG, Federal University of Minas Gerais.

* Diabetes was strongly correlated with high-grade dyslipidemia and therefore excluded from the multivariate model.

[†] Multivariate results generated by substituting nadir CD4 with this variable in the main adjusted model.

Table 3

Factors associated with all-cause mortality

Characteristic	Deaths	Person-years	Rate per 1000 person-years (95% CI)	Univariate		Multivariate	
				HR (95% CI)	P	HR (95% CI)	P
Overall	418	25 110.7	16.6 (15.1–18.3)	1.0	1.0	1.0	1.0
Age, years							
<35	91	7321.7	12.4 (10.1–15.3)	1.2 (1.0–1.6)	0.11	1.2 (0.9–1.6)	0.16
35–44	146	9401.0	15.5 (13.2–18.3)	1.5 (1.1–2.0)	<0.01	1.5 (1.1–2.0)	0.01
45–54	116	6067.7	19.1 (15.9–22.9)	2.2 (1.6–3.0)	<0.01	2.0 (1.4–3.0)	<0.01
55+	65	2320.4	28.0 (22.0–35.7)	1.0	1.0	1.0	1.0
Sex							
Female	139	8907.6	15.6 (13.2–18.4)	1.1 (0.9–1.3)	0.36	1.3 (1.0–1.6)	0.05
Male	279	16 203.1	17.2 (15.3–19.4)	1.0	1.0	1.0	1.0
Race							
White	209	14 275.6	14.6 (12.8–16.8)	1.5 (1.1–1.9)	<0.01	1.3 (1.0–1.7)	0.07
Black	89	4185.5	21.3 (17.3–26.2)	1.3 (1.0–1.6)	0.03	1.3 (1.0–1.7)	0.02
Mixed black	103	5516.2	18.7 (15.4–22.6)	1.1 (0.6–1.7)	0.84	0.9 (0.5–1.5)	0.61
Other	17	1133.5	15.0 (9.3–24.1)	1.0	1.0	1.0	1.0
HIV exposure							
Heterosexual	254	14 124.6	18.0 (15.9–20.3)	0.6 (0.5–0.8)	<0.01	0.8 (0.6–1.1)	0.20
Men who have sex with men	81	7396.5	11.0 (8.8–13.6)	2.4 (1.7–3.3)	<0.01	1.7 (1.2–2.5)	<0.01
Intravenous drug use	40	924.1	43.3 (31.8–59.0)	0.8 (0.6–1.1)	0.16	1.0 (0.7–1.4)	0.92
Other	43	2665.5	16.1 (12.0–21.8)	1.0	1.0	1.0	1.0
Past CVD event							
No	391	24 474.1	16.0 (14.5–17.6)	2.6 (1.7–3.9)	<0.01	1.7 (1.1–2.7)	0.01
Yes	27	636.6	42.4 (29.1–61.8)	1.0	1.0	1.0	1.0
Current hypertension							
No	350	22 007.4	15.9 (14.3–17.7)	1.4 (1.0–1.8)	0.02	1.0 (0.8–1.4)	0.78
Yes	68	3103.3	21.9 (17.3–27.8)	1.0	1.0	1.0	1.0
Current high-grade dyslipidemia							
No	356	22 632.8	15.7 (14.2–17.5)	1.5 (1.2–2.0)	<0.01	1.2 (0.9–1.7)	0.22
Yes	62	2478.0	25.0 (19.5–32.1)	1.0	1.0	1.0	1.0
Current diabetes							
No	373	23 683.0	15.7 (14.2–17.4)	2.0 (1.4–2.7)	<0.01	1.6 (1.1–2.2)	0.02
Yes	45	1427.8	31.5 (23.5–42.2)	1.0	1.0	1.0	1.0
Smoking status at ART initiation							
Never	75	5832.9	12.9 (10.3–16.1)	1.5 (1.2–1.9)	<0.01	1.3 (0.9–1.7)	0.13
Ever	256	13276.5	19.3 (17.1–21.8)	–	–	–	–
Unknown	87	6001.3	14.5 (11.7–17.9)	1.0	1.0	1.0	1.0
Nadir CD4 at ART initiation*, cells/mm ³							
>250	100	7490.8	13.3 (11.0–16.2)	–	–	–	–

Characteristic	Deaths	Person-years	Rate per 1000 person-years (95% CI)	Univariate		Multivariate	
				HR (95% CI)	P	HR (95% CI)	P
	166	9583.2	17.3 (14.9–20.2)	1.3 (1.0–1.7)	0.04	1.1 (0.9–1.4)	0.45
	123	6840.2	18.0 (15.1–21.5)	1.4 (1.0–1.8)	0.03	1.1 (0.8–1.5)	0.43
	29	1196.6	24.2 (16.8–34.9)	–	–	–	–
Current CD4, cells/mm ³	75	12 113.0	6.2 (4.9–7.8)	1.0	1.0	1.0	1.0
	58	5580.7	10.4 (8.0–13.4)	1.9 (1.3–2.6)	<0.01	1.6 (1.1–2.3)	0.01
	100	4357.7	22.9 (18.9–27.9)	4.3 (3.1–5.8)	<0.01	3.1 (2.3–4.3)	<0.01
	171	2527.8	67.6 (58.2–78.6)	12.3 (9.3–16.2)	<0.01	7.7 (5.6–10.6)	<0.01
	14	531.5	26.3 (15.6–44.5)	–	–	–	–
Current CD4/CD8 ratio*	57	7189.6	7.9 (6.1–10.3)	1.0	1.0	1.0	1.0
	74	7680.5	9.6 (7.7–12.1)	1.3 (0.9–1.8)	0.16	1.1 (0.8–1.5)	0.70
	238	7613.9	31.3 (27.5–35.5)	4.4 (3.3–6.0)	<0.01	2.5 (1.8–3.4)	<0.01
	49	2626.8	18.7 (14.1–24.7)	–	–	–	–
Current HIV viral load	230	21 072.4	10.9 (9.6–12.4)	1.0	1.0	1.0	1.0
	172	3482.5	49.4 (42.5–57.4)	4.6 (3.7–5.5)	<0.01	2.1 (1.7–2.7)	<0.01
	16	555.9	28.8 (17.6–47.0)	–	–	–	–
AIDS diagnosis prior to ART initiation	236	15 554.5	15.2 (13.4–17.2)	1.0	1.0	1.0	1.0
	182	9556.2	19.0 (16.5–22.0)	1.3 (1.1–1.6)	0.01	1.1 (0.9–1.3)	0.56
Year of ART initiation	112	6554.9	17.1 (14.2–20.6)	1.0	1.0	1.0	1.0
	251	12 721.3	19.7 (17.4–22.3)	1.2 (1.0–1.6)	0.09	1.3 (1.0–1.6)	0.06
	55	5834.5	9.4 (7.2–12.3)	0.6 (0.4–0.8)	<0.01	0.7 (0.5–1.0)	0.04
HIV clinic	42	4151.0	10.1 (7.5–13.7)	1.0	1.0	1.0	1.0
	12	1022.8	11.7 (6.7–20.7)	1.3 (0.7–2.5)	0.39	1.2 (0.6–2.4)	0.60
	162	9394.0	17.2 (14.8–20.1)	1.9 (1.3–2.7)	<0.01	1.6 (1.1–2.3)	0.01
	115	5245.9	21.9 (18.3–26.3)	2.4 (1.7–3.4)	<0.01	1.8 (1.2–2.6)	<0.01
	52	2043.8	25.4 (19.4–33.4)	2.7 (1.8–4.1)	<0.01	1.6 (1.0–2.5)	0.03
	9	991.0	9.1 (4.7–17.5)	1.0 (0.5–2.0)	0.98	0.7 (0.4–1.6)	0.45
	26	2262.3	11.5 (7.8–16.9)	1.3 (0.8–2.1)	0.34	1.1 (0.6–1.7)	0.84

CI, confidence interval; HR, sub-distribution hazard ratio; CVD, cardiovascular disease; ART, antiretroviral therapy; CRT, São Paulo State Department of Health STD/AIDS Referral and Training Center; HUPES, Professor Edgard Santos University Hospital; INI, National Institute of Infectology Evandro Chagas – Fiocruz; UFMG, Federal University of Minas Gerais.

* Multivariate results generated by substituting current CD4 with this variable in the main adjusted model.